Premium
Low‐dose cytosine arabinoside regimen induced a complete remission with normal karyotypes in a case with hypoplastic acute myeloid leukaemia with No. 8‐trisomy: in vitro and in vivo evidence for normal haematopoietic recovery
Author(s) -
Tagawa M.,
Shibata J.,
Tomonaga M.,
Amenomori T.,
Yoshida Y.,
Kuriyama K.,
Matsuo T.,
Sadamori N.,
Ichimaru M.
Publication year - 1985
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1985.tb07442.x
Subject(s) - trisomy , cytarabine , karyotype , bone marrow , myeloid , cytosine , medicine , clone (java method) , daunorubicin , regimen , trisomy 8 , immunology , biology , myeloid leukemia , leukemia , gastroenterology , chromosome , genetics , dna , gene
S ummary Complete remission was achieved in a case of hypoplastic acute myeloid leukaemia with chromosomal abberation of No. 8‐trisomy by giving very low dose of cytosine arabinoside (ara‐C), 10 mg (7.5 mg/m 2 )/d, by 24 h continuous intravenous infusion for 20 d. We observed a definite cytoreduction phase in the bone marrow (BM) before normal haematopoiesis resumed. The remission BM showed only normal karyotypes in all metaphases examined. Granulocyte/macrophage colonies and erythroid bursts recovered sufficiently in numbers and cytogenetic study on single colonies and bursts revealed only normal karyotypes. These observations provide evidence that a low dose ara‐C regimen can induce remission by cytoreduction which diverts the growth advantage from the leukaemic clone to the normal clones.